Clifford Coile, MD
Pulmonary Disease · Covington, LANPI 1881073062
Payments from drug & device makers
Across 161 payments — averaging $35.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- AstraZeneca$429
- GSK$417
- Boehringer Ingelheim$406
- Actelion Pharmaceuticals US, Inc.$370
- AbbVie$274
- plus $2K from 18 others
What the payments were for
- Travel & lodging$1,74030%
- Food & beverage$3,99270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 24 | $2,155 |
| AstraZeneca | 8 | $429 |
| GSK | 38 | $417 |
| Boehringer Ingelheim | 12 | $406 |
| Actelion Pharmaceuticals US, Inc. | 8 | $370 |
| AbbVie | 13 | $274 |
| Sanofi | 13 | $261 |
| Pfizer | 15 | $219 |
| Astellas Pharma US Inc | 4 | $188 |
| United Therapeutics Corporation | 4 | $175 |
| Viatris Specialty LLC | 2 | $134 |
| Johnson & Johnson | 1 | $133 |
| Inspire Medical Systems, Inc. | 2 | $121 |
| Livanova USA, Inc. | 1 | $117 |
| Mallinckrodt Enterprises LLC | 3 | $79 |
| Regeneron Healthcare Solutions, Inc. | 2 | $62 |
| Merck | 2 | $41 |
| Novartis | 2 | $29 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Tempus AI, Inc | 1 | $22 |
| Bayer | 1 | $22 |
| Insmed, Inc. | 1 | $18 |
| Vapotherm Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,666
- TEZSPIRE$346
- UPTRAVI$243
- OPSUMIT$243
- Monarch Platform$133
- CRESEMBA$123
- OFEV$120
- LifeSPARC$117
- Yupelri$109
- Inspire$101
How this compares
$5,732 in reported general payments places this provider in the 55th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 193 | $146,837 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 49 | $39,267 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 52 | $28,694 |
| Spiriva RespimatTiotropium Bromide | 27 | $22,111 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 42 | $20,902 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $20,692 |
| Pirfenidone | 14 | $15,732 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $6,920 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 160 | $5,389 |
| Wixela InhubFluticasone Propion/Salmeterol | 42 | $4,442 |
| Varenicline Tartrate | 17 | $3,849 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $2,976 |
| Mycophenolate Mofetil | 17 | $1,675 |
| Ventolin HfaAlbuterol Sulfate | 16 | $1,044 |
| Montelukast Sodium | 79 | $678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $417 | $188,432262 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $406 | $50,80579 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $429 | $46,18668 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in Covington
- Richard CaseyCovington$218K
- Rachele GibsonCovington$24K
- Ricardo BlancoCovington$17K
- David GreenShreveport$2M
- Joseph LaskyNew Orleans$1.9M
- Leonardo SeoaneNew Orleans$1.6M
- Ross KlingsbergNew Orleans$1.2M
- Juzar AliNew Orleans$775K
- Hollis O NealBaton Rouge$682K
- Andrea EspinozaHouma$655K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.